Ignite Creation Date:
2025-12-24 @ 12:48 PM
Ignite Modification Date:
2026-02-20 @ 1:35 PM
Study NCT ID:
NCT02811861
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2024-11-01
First Post:
2016-06-21
Is Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Lenvatinib/Everolimus or Lenvatinib/Pembrolizumab Versus Sunitinib Alone as Treatment of Advanced Renal Cell Carcinoma
Sponsor:
Eisai Inc.
Organization:
Organization Data
Organization:
Class:
INDUSTRY
Study ID:
E7080-G000-307
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
INDUSTRY
Responsible Party:
Responsible Party Title:
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None
Collaborators
Collaborators
| Name | Class | View |
|---|---|---|
| None | INDUSTRY | View |